Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy

Reuters

Mar 05

Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination <a href="https://laohu8.com/S/MSTR">Strategy</a>

Skye Bioscience Inc. released a corporate presentation outlining its obesity and metabolic disease pipeline, highlighting nimacimab, a peripherally restricted CB1-inhibiting antibody being evaluated in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13 percent weight loss at 26 weeks for the combination versus semaglutide alone, and interim extension data indicating 22.3 percent total weight loss at 52 weeks with no plateau observed. It also reports reduced post-treatment weight regain in off-therapy follow-up for the combination versus semaglutide alone, along with a tolerability profile that did not show additive gastrointestinal burden or neuropsychiatric adverse events in the combination arm. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2617754170"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617754170\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617754170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617754170","market":"nz","top_or_hot":-1,"title":"Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination <a href=\"https://laohu8.com/S/MSTR\">Strategy</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience Inc.</a> released a corporate presentation outlining its obesity and metabolic disease pipeline, highlighting nimacimab, a peripherally restricted CB1-inhibiting antibody being evaluated in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13 percent weight loss at 26 weeks for the combination versus semaglutide alone, and interim extension data indicating 22.3 percent total weight loss at 52 weeks with no plateau observed. It also reports reduced post-treatment weight regain in off-therapy follow-up for the combination versus semaglutide alone, along with a tolerability profile that did not show additive gastrointestinal burden or neuropsychiatric adverse events in the combination arm. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSkye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-05 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination <a href=\"https://laohu8.com/S/MSTR\">Strategy</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience Inc.</a> released a corporate presentation outlining its obesity and metabolic disease pipeline, highlighting nimacimab, a peripherally restricted CB1-inhibiting antibody being evaluated in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13 percent weight loss at 26 weeks for the combination versus semaglutide alone, and interim extension data indicating 22.3 percent total weight loss at 52 weeks with no plateau observed. It also reports reduced post-treatment weight regain in off-therapy follow-up for the combination versus semaglutide alone, along with a tolerability profile that did not show additive gastrointestinal burden or neuropsychiatric adverse events in the combination arm. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SKYE","symbol_name":"Skye Bioscience Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLbTZ46y:1","article_id":"2617754170","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617754170","pubTimestamp":1772712583,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Skye Bioscience Inc. released a corporate presentation outlining its obesity and metabolic disease pipeline, highlighting nimacimab, a peripherally restricted CB1-inhibiting antibody being evaluated in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13 percent weight loss at 26 weeks for the combination versus semaglutide alone, and interim extension data indicating 22.3 percent total weight loss at 52 weeks with no plateau observed. It also reports reduced post-treatment weight regain in off-therapy follow-up for the combination versus semaglutide alone, along with a tolerability profile that did not show additive gastrointestinal burden or neuropsychiatric adverse events in the combination arm. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SKYE":"Skye Bioscience Inc.","BK4139":"生物科技"},"translate_title":"Skye Bioscience发布关于Nimacimab-Semaglutide肥胖组合策略的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SKYE":0.9},"content_text":"Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy\n\n\nSkye Bioscience Inc. released a corporate presentation outlining its obesity and metabolic disease pipeline, highlighting nimacimab, a peripherally restricted CB1-inhibiting antibody being evaluated in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13 percent weight loss at 26 weeks for the combination versus semaglutide alone, and interim extension data indicating 22.3 percent total weight loss at 52 weeks with no plateau observed. It also reports reduced post-treatment weight regain in off-therapy follow-up for the combination versus semaglutide alone, along with a tolerability profile that did not show additive gastrointestinal burden or neuropsychiatric adverse events in the combination arm. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}